Anavex Life Sciences
Yahoo Finance • 14 hours ago
Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease
Findings underpin the scientific rationale for Anavex’s targeted autophagy approach with orally administered blarcamesine Convergence of impaired autophagy and synaptic dysfunction across neurodevelopmental and neurodegenerative condition... Full story
Yahoo Finance • 16 days ago
Anavex Life Sciences Provides Comprehensive Regulatory Update
Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer’s disease Additional data submitted to the U.S. FDA with the objective to discuss potential pathways toward... Full story
Yahoo Finance • 21 days ago
Anavex drops after pulling EU marketing application for Alzheimer’s therapy
[An arrow pointing downwards on top of a pile of US dollar bills.] Anavex Life Sciences (AVXL [https://seekingalpha.com/symbol/AVXL]) lost ~18% in the premarket on Wednesday after the company announced that it withdrew the marketing autho... Full story
Yahoo Finance • 2 months ago
3 Promising Penny Stocks With At Least $200M Market Cap
As the United States stock market kicks off February with a strong start, major indexes like the Dow Jones and S&P 500 have shown impressive gains. In this context of optimism, penny stocks—often overlooked due to their smaller size or you... Full story
Yahoo Finance • 2 months ago
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson'... Full story
Yahoo Finance • 3 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at... Full story
Yahoo Finance • 4 months ago
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's
[Alzheimers Concept Horizontal] travellinglight * Anavex Life Sciences (AVXL [https://seekingalpha.com/symbol/AVXL]) has formally asked the European Medicines Agency to re-examine its opinion [https://seekingalpha.com/news/4531047-ema-r... Full story
Yahoo Finance • 4 months ago
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson'... Full story
Yahoo Finance • 4 months ago
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
LOS ANGELES, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life Sciences Corp. (“Anavex” or “the Company”)... Full story
Yahoo Finance • 5 months ago
SA Quant ranks Goldman's small-cap stocks with largest short interest
[Multi screen fintech investing gold and silver trading on digital screen corporating with AI artificial intelligence financial business data on commodity investment] primeimages Goldman Sachs analysts last week identified 50 small-cap st... Full story
Yahoo Finance • 5 months ago
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson'... Full story
Yahoo Finance • 5 months ago
Anavex Life Sciences GAAP EPS of -$0.11 beats by $0.04
* Anavex Life Sciences press release [https://seekingalpha.com/pr/20319558-anavex-life-sciences-reports-fiscal-2025-fourth-quarter-financial-results-and-provides] (AVXL [https://seekingalpha.com/symbol/AVXL]): Q4 GAAP EPS of -$0.11 beats... Full story
Yahoo Finance • 5 months ago
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
Company to host a webcasttoday at 8:30 a.m. Eastern Time NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing... Full story
Yahoo Finance • 5 months ago
Here are the major earnings before the open Tuesday
Major earnings expected before the bell on Tuesday include: * Alibaba Group Holding Limited (BABA [https://seekingalpha.com/symbol/BABA]) * NIO (NIO [https://seekingalpha.com/symbol/NIO]) * Best Buy Co. (BBY [https://seekingalpha.co... Full story
Yahoo Finance • 5 months ago
Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson'... Full story
Yahoo Finance • 5 months ago
Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson'... Full story
Yahoo Finance • 5 months ago
Anavex tumbles as Alzheimer’s therapy faces EU rejection
[Alzheimers Concept Horizontal] travellinglight/iStock via Getty Images Anavex Life Sciences (AVXL [https://seekingalpha.com/symbol/AVXL]) lost ~47% in the premarket on Friday after a group of experts appointed by the EU drug regulator, t... Full story
Yahoo Finance • 5 months ago
Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease
Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company’s Alzheimer's Disease clinical trial results NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) --... Full story
Yahoo Finance • 5 months ago
Anavex dips amid oral hearing scheduled for lead drug in EU
[An arrow pointing downwards on top of a pile of US dollar bills.] * Shares of Anavex Life Sciences (AVXL [https://seekingalpha.com/symbol/AVXL]) fell as much as ~9% on Monday after the EU drug regulator, the European Medicines Agency (... Full story
Yahoo Finance • 6 months ago
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group
ADAS-Cog13 difference −12.78 (P < 0.0001) with oral blarcamesine treatment compared to ADNI control group at Week 144 77.4 Weeks (17.8 Months) ‘time saved’ with oral blarcamesine compared to ADNI Restoring impaired Autophagy − preceding... Full story
